20 December 2016 - Neurolixis CSO to present at Encéphale Congress in Paris

Adrian Newman-Tancredi, PhD, DSc, will present at the forthcoming Encéphale Congress to be held January 18-20, 2017 in Paris, France. Dr. Newman-Tancredi has been invited in his capacity as Chief Scientific Officer of Neurolixis to give a lecture on emerging drug discovery concepts for the development of novel antidepressants.

Dr. Newman-Tancredi's presentation will be part of the plenary session entitled "Psychopharmacology in the third millennium" on Wednesday 18 January 2017 and will focus on prospects for improved treatment of depressive disorders using highly selective 'biased agonists' targeting cortical serotonin 5-HT1A receptors.  

For full details of the Encéphale Congress program see the meeting website.

15e Congrès de l'Encéphale

24 May 2016 - Just Published: biased agonism of NLX-101 demonstrated using pharmacoMRI brain imaging

A new publication shows the 'biased agonist' profile of the Neurolixis drug, NLX-101, by using pharmacoMRI imaging in rat brain. NLX-101 elicited increases in energy usage (measured as Blood Oxygen Level Dependence ; BOLD) in frontal cortex, whereas other serotonin 5-HT1A agonists showed distinct stimulation patterns.

The study was carried out within the CERMEP-Imaging platform of the Lyon University Hospital by a team led by Prof. Luc Zimmer, an expert in brain imaging of serotonergic systems. The results corroborate the novel activtiy of NLX-101 and support the rationale for its development in disorders afecting mood and cognition, including Rett syndrome.


Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study.

Becker G, Bolbos R, Costes N, Redouté J, Newman-Tancredi A, Zimmer L   Free PDF  pdf_symbol
Sci Rep. 2016 May 23;6:26633. doi: 10.1038/srep26633.